Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 1Phase 1 1

Status

Completed 4

Sponsor Class

INDUSTRY 5OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Other solid neoplasm 1

Conditions

Stomach Neoplasms 1Solid Tumor 1Neoplasms 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Cyclophosphamide 956Radiotherapy 847Cisplatin 757Gemcitabine 657Carboplatin 603Docetaxel 598Paclitaxel 585Bevacizumab 580Fluorouracil 504Oxaliplatin 458Rituximab 453Surveys and Questionnaires 449Capecitabine 440Dexamethasone 428Doxorubicin 424Etoposide 411Irinotecan 389Cytarabine 376Filgrastim 369pembrolizumab 330Leucovorin 305Nivolumab 296fludarabine phosphate 294Melphalan 288Magnetic Resonance Spectroscopy 281Peripheral Blood Stem Cell Transplantation 279Blood Specimen Collection 279Methotrexate 276Lenalidomide 276Cetuximab 270

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × OTHER × ARRY-334543 × Clear all
NCT03130790 2022-02-15

Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)

ASLAN Pharmaceuticals

Phase 2/3 Completed
52 enrolled
Gastrointestinal

Stomach Neoplasms

NCT03093870 2021-08-03

TreeTopp

ASLAN Pharmaceuticals

Phase 2/3 Completed
151 enrolled 18 charts
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Neoplasms

NCT02648425 2018-10-25

Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine

ASLAN Pharmaceuticals

Phase 1 Completed
31 enrolled
Other solid neoplasm

Solid Tumor

NCT02609958 2018-05-29

ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy

ASLAN Pharmaceuticals

Phase 2 Completed
32 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡